Xuanzhu Biology was selected as one of the "Top 10 Innovative Biopharmaceutical Companies in China" in the 2022 Future Medical Top 100 List.
About the Future Medical Top 100 List
Established in 2015, the Future Medical Top 100 list, launched by VB100, DMA, and Danshell Research Institute, is the first domestic list of innovative medical companies that are not publicly listed. It aims to select the true representatives of the future of medical innovation in China, discover the core strength of China's future medical industry, and promote the innovative transformation process of the health and medical industry. It is currently the most watched annual selection in the life sciences and healthcare sector by industry and capital.
Xuanzhu Bio is an innovative pharmaceutical subsidiary of the large Chinese pharmaceutical company, Four Rings Pharmaceutical Holdings Group (0460.HK). It has a full industrial chain layout, consisting of multiple subsidiaries that cover drug discovery, pre-clinical research, clinical development, production, and sales.
The company focuses on major disease areas such as tumors, digestive system diseases, and metabolic diseases. It is committed to continuously developing and commercializing innovative drugs with core independent intellectual property rights based on new targets and mechanisms. It leads innovation through a combination of independent research and development and collaboration with cutting-edge technologies. The core goal is to be clinically driven, addressing urgent clinical needs and unmet medical needs. Xuanzhu currently has a rare product pipeline in China that simultaneously covers various types of products, including small molecule chemical drugs (including molecular glues and targeted protein degraders), monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs). It is an outstanding company in the field of innovative pharmaceuticals in China.
